Should We Sequence the DNA of Every Cancer Patient?
By Antonio Regalado,
MIT Technology Review
| 06. 14. 2016
A startup called Strata Oncology says it plans to give away advanced genetic tests to 100,000 patients struggling with cancer. But there's a profit motive: it hopes to identify patients with specific rare DNA errors and steer them to drug companies.
Strata, which was founded last year and has raised $12 million from investors, says it is set up to run 50,000 next-generation sequencing tests a year. Such tests probe the DNA of tumor tissue, searching for mutations in hundreds of genes at once, hoping to surface clues about what drug a patient should be taking.
Similar tests are already offered commercially to doctors by several companies, including Foundation Medicine of Cambridge, Massachusetts, and can cost $5,000 each.
Continue reading on MIT Technology Review
Image via Wikipedia
Related Articles
By Jessica Mouzo, El País | 10.03.2025
DNA is the molecule of life: this double-helix structure, present in every cell in the body and organized into fragments called genes, stores the instructions for making organisms function. It is a highly precise biological machine, but sometimes it breaks...
By Katherine Bourzac, Nature | 09.25.2025
A judge in New York rejected a request on 23 September to disqualify the use of cutting-edge DNA sequencing as evidence in a case against an alleged serial killer. The ruling paves the way for a type of DNA analysis...
By Claire Robinson, GMWatch | 09.29.2025
According to an article on BBC News, the Quadram Institute in Norwich is recruiting 76 people with low vitamin D to take part in the ViTaL-D Study, where some participants will eat soup containing tomatoes that have been genetically...
By Margaux MacColl, The San Francisco Standard | 09.17.2025
Designer babies are coming soon to an IVF clinic near you.
Nucleus Genomics, founded by Kian Sadeghi in 2020, when he was just 20, got its start analyzing genomes to weigh a person’s risk of everything from cancer to ADHD...